Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab
暂无分享,去创建一个
Albert Lai | Whitney B. Pope | Benjamin M. Ellingson | Timothy F. Cloughesy | Shadi Lalezari | Phioanh L. Nghiemphu | T. Cloughesy | P. Mischel | W. Pope | P. Nghiemphu | A. Lai | B. Ellingson | Paul S. Mischel | Taryar Zaw | Kourosh Motevalibashinaeini | T. Zaw | S. Lalezari | Kourosh Motevalibashinaeini
[1] V. Tombolini,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients , 2008, Journal of Neuro-Oncology.
[2] K Tsuchiya,et al. Preliminary evaluation of fluid-attenuated inversion-recovery MR in the diagnosis of intracranial tumors. , 1996, AJNR. American journal of neuroradiology.
[3] Kathleen M. Schmainda,et al. Comparison of cytotoxic and anti-angiogenic treatment responses using functional diffusion maps in FLAIR abnormal regions , 2009 .
[4] R W Cox,et al. Real‐time 3D image registration for functional MRI , 1999, Magnetic resonance in medicine.
[5] T. Mikkelsen,et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan , 2009, Journal of Neuro-Oncology.
[6] B A Kall,et al. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. , 1987, Journal of neurosurgery.
[7] G. Yancopoulos,et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.
[8] Albert Lai,et al. Time course of imaging changes of GBM during extended bevacizumab treatment , 2008, Journal of Neuro-Oncology.
[9] P. Wen,et al. Bevacizumab for recurrent malignant gliomas , 2008, Neurology.
[10] Georg Breier,et al. Molecular Mechanisms of Developmental and Tumor Angiogenesis , 1994, Brain pathology.
[11] Wei Chen,et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Darell D. Bigner,et al. Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.
[14] Timothy D Johnson,et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R L Ehman,et al. Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. , 1988, Radiology.
[16] S. Nelson,et al. Bevacizumab and chemotherapy for recurrent glioblastoma , 2009, Neurology.
[17] L. Deangelis,et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma , 2009, Neurology.
[18] Paul S Mischel,et al. MR imaging correlates of survival in patients with high-grade gliomas. , 2005, AJNR. American journal of neuroradiology.
[19] D. Blumenthal,et al. Treatment with bevacizumab and irinotecan for recurrent high‐grade glial tumors , 2008, Cancer.
[20] T. Byrne,et al. Imaging of gliomas. , 1994, Seminars in oncology.
[21] H. Köstler,et al. Diagnostic value of the fast-FLAIR sequence in MR imaging of intracranial tumors , 2000, European Radiology.
[22] M. Battaglini,et al. Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis. , 2008, Archives of neurology.
[23] P. Wen,et al. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. , 2009, Cancer research.
[24] Ucla Medical. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy , 2006 .
[25] B A Kall,et al. Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. , 1987, Mayo Clinic proceedings.
[26] H. Mehdorn,et al. Expression of VEGF and its receptors in different brain tumors , 2005, Neurological research.
[27] M Brant-Zawadzki,et al. Magnetic resonance of the brain: the optimal screening technique. , 1984, Radiology.
[28] Matthew S. Brown,et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. , 2009, Radiology.
[29] P. LaViolette,et al. Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas , 2011, Journal of Neuro-Oncology.
[30] T. Mikkelsen,et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] J. Uhm. Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group , 2010 .
[32] R. Mirimanoff,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[33] J Debus,et al. Fast fluid‐attenuated inversion‐recovery (FLAIR) MRI in the assessment of intraaxial brain tumors , 1998, Journal of magnetic resonance imaging : JMRI.
[34] R. Tanaka,et al. Magnetic resonance imaging and histopathology of cerebral gliomas , 2004, Neuroradiology.
[35] A. Mackay,et al. In vivo measurement of T2 distributions and water contents in normal human brain , 1997, Magnetic resonance in medicine.
[36] P. LaViolette,et al. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity , 2010, Journal of magnetic resonance imaging : JMRI.
[37] X Golay,et al. MR imaging of the human brain at 1.5 T: regional variations in transverse relaxation rates in the cerebral cortex. , 2001, AJNR. American journal of neuroradiology.
[38] Paul S Mischel,et al. Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. , 2011, Neuro-oncology.
[39] Timothy D Johnson,et al. The parametric response map is an imaging biomarker for early cancer treatment outcome , 2009, Nature Medicine.
[40] P. Kelly,et al. High-grade glioma before and after treatment with radiation and Avastin: initial observations. , 2008, Neuro-oncology.
[41] Tracy T Batchelor,et al. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. , 2007, Trends in molecular medicine.
[42] Bradford A Moffat,et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. , 2005, Proceedings of the National Academy of Sciences of the United States of America.